Ruthenium Complexes for Selective Galectin-1 Binding Cavities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an ongoing need for novel galectin inhibitors that exhibit selectivity towards galectin 1, particularly for the treatment of cancerous diseases and HIV infection, as existing inhibitors often lack specificity for galectin-1 and have limited efficacy in inhibiting its functions.
Innovation Solution
Development of ruthenium complexes with a three-dimensional structure that selectively inhibit galectin 1 by engaging in additional interactions within the target protein's binding site, including electrostatic interactions with negatively charged amino acids, and are designed to be active in both extracellular and intracellular environments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing galectin inhibitors are used, then galectin binding is inhibited, but selectivity for galectin-1 is insufficient
Solution Approach 1:
The patent applies local quality by designing ruthenium complexes with specific spatial arrangements of aromatic rings and hydroxyl groups that are optimized for interaction with galectin-1's binding cavity. The complex features a specific configuration where aromatic rings are positioned to interact with tryptophan residues and hydroxyl groups are oriented for hydrogen bonding with conserved amino acids in galectin-1, creating localized high-affinity interaction sites that confer selectivity.
Solution Approach 2:
The patent employs composite materials by creating ruthenium complexes that combine multiple functional moieties: aromatic rings for π-π interactions, hydroxyl groups for hydrogen bonding, and a ruthenium center with specific coordination geometry. This composite structure integrates different interaction mechanisms into a single molecule that achieves both high affinity and selectivity for galectin-1.
2Reliability
If inhibitors with high affinity for galectin-3 are developed, then galectin-3 functions are inhibited, but galectin-1 selectivity is compromised
Solution Approach 1:
The ruthenium complex exhibits local quality through its asymmetric structure where specific aromatic rings and hydroxyl groups are positioned to recognize galectin-1's unique binding cavity features. The complex forms specific interactions with galectin-1's conserved amino acids (histidine, arginine, asparagine) and tryptophan residues, creating a localized recognition interface that distinguishes galectin-1 from other galectins.
Solution Approach 2:
The patent applies parameter changes by optimizing the spatial parameters of the ruthenium complex - specifically the distances and angles between aromatic rings, hydroxyl groups, and the ruthenium center - to match the geometric parameters of galectin-1's binding cavity. This geometric optimization creates high affinity and selectivity simultaneously.
3Ease of manufacture
If two-dimensional planar structures are used for inhibitors, then synthesis is simplified, but binding cavity occupancy is reduced
Solution Approach 1:
The patent transitions from two-dimensional planar structures to three-dimensional folded configurations in the ruthenium complex. The complex adopts a compact 3D structure with aromatic rings arranged in a folded pattern that projects into the binding cavity from multiple dimensions, maximizing occupancy and interaction opportunities within the galectin-1 binding site.
Solution Approach 2:
The ruthenium complex serves as a composite material integrating multiple functional elements in three-dimensional space: aromatic rings for π-π stacking, hydroxyl groups for hydrogen bonding, and a ruthenium coordination core that provides structural rigidity. This composite 3D architecture enables simultaneous maximization of binding cavity occupancy and interaction specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ruthenium complexes demonstrate enhanced inhibition potency and selectivity for galectin 1, potentially improving treatment outcomes for cancer and HIV infection by inhibiting galectin-1 functions effectively.
Implementation Method 1
engaging in additional interactions within the target protein's binding site, including electrostatic interactions with negatively charged amino acids
Implementation Method 2
The interaction is mediated by 6 amino acids in the binding cavity by hydrogen bonds between these amino acids (typically histidine, arginine, and asparagine) and the disaccharide hydroxyl groups
Implementation Method 3
This enhanced affinity is attributed to both π-π interactions between aromatic structures and aromatic amino acids within galectins
Implementation Method 4
Another ligand, B, is selected from the group comprising monovalent negatively charged ligands and neutral ligands
Data Source
AI summary
The presented invention relates to compounds of general formula (I), wherein R1, R2, R3, R4 a R are independently selected from the group comprising H and (C1 to C6)alkyl; n is 1 or 2; X is CH or N; D, Y, and Z are independently CH, N or O; R is independently H or acyl or thioacyl; B is selected from the group comprising monovalent negatively charged ligands and neutral ligands; and A is a structure (II) or (III) The invention further relates to a method of their preparation and their use.